The US Supreme Court has agreed to delve into a contentious patent dispute between Sandoz and Amgen over how quickly lower-cost biosimilar drugs can make it to market.
This has huge implications for how all biosimilars are marketed and priced, because these drugs represent some $44 billion in health care cost savings through 2024. Biosimilars are expected to be priced at 10 to 30 percent less than their branded counterparts.
The case between Amgen and Sandoz centers on when, precisely, the makers of biosimilars have to notify the manufacturer of the branded drug they’re mimicking.
About the Author Reprints
